A Phase I Study of Ridaforolimus (MK8669) and MK0646 in Patients With Advanced Cancer
Ridaforolimus (MK8669/AP23573) was also known as deforolimus until May 2009
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the toxicity profile, maximum tolerated dose and recommended phase II dose.
MTD from Day 1 to Day 28 in Cycle 1 for disease progression
United States: Food and Drug Administration